Pacific Biosciences of California

Pacific Biosciences of California is an American biotechnology company that designs, develops, and manufactures sequencing systems to help scientists resolve genetically complex problems. The сompany offers Single Molecule and Real-Time (SMRT) technology that enables real-time analysis of biomolecules with single molecule resolution. The company was founded based on research done at Cornell University that combined semiconductor processing and photonics with biotechnology research.
Pacific Biosciences of California stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Pacific Biosciences of California balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Pacific Biosciences of California cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Pacific Biosciences of California multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Pacific Biosciences of California profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Pacific Biosciences of California assets
Pacific Biosciences of California cash flows

Pacific Biosciences of California dividend policy

The company doesn't provide dividend

Pacific Biosciences of California shares

TickerNameTypeNominal valueISINPrice
PACB:USPacific Biosciences of CaliforniaCommon share-US69404D1081$3.68
Pacific Biosciences of California news
05.05.2022
Pacific Biosciences of California's GAAP loss for 3 months of 2022 was $81.499 million, down 6.8% from $87.435 million in the prior year. Revenue increased 14.4% to $33.173 million from $28.997 million a year earlier.
Source: {source} pictogram investor.pacificbiosciences.com
Pictogram next
16.02.2022
Pacific Biosciences of California's GAAP loss for 2021 was $181.223 million, compared to a profit of $29.403 million in the previous year. Revenue increased 65.4% to $130.513 million from $78.893 million a year earlier.
Source: {source} pictogram investor.pacificbiosciences.com
Pictogram next
03.11.2021
Pacific Biosciences of California reported a GAAP loss of $111.894 million for 9M 2021, up 2.5 times from $45.532 million in the previous year. Revenues increased 82.6% to $94.494 million from $51.757 million a year earlier.
Source: {source} pictogram investor.pacificbiosciences.com
Pictogram next
21.09.2021
Pacific Biosciences completed its $800 million acquisition of Omniome, which is developing a short-read sequencing platform capable of high accuracy. Pacific Biosciences paid $300 million and 9.4 million of its common stock, and will pay an additional $200 million if certain milestones are reached.
Source: {source} pictogram investor.pacificbiosciences.com
Pictogram next
All Pacific Biosciences of California news
General information
Company namePacific Biosciences of California
Tags#katie wood's choice, #biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address1305 O'Brien Drive Menlo Park, CA 94025 United States
Websiteinvestor.pacificbiosciences.com
Information disclosurewww.sec.gov